复方黄芪注射液对急性重型颅脑损伤患者血清NSE，MBP和S-100B含量的影响

目的观察复方黄芪注射液对急性重型颅脑损伤患者血清神经元特异性烯醇化酶（NSE），髓鞘碱性蛋白（MBP）和S-100蛋白B（S-100B）含量的影响。方法按标准选取急性重型颅脑损伤患者196例，随机分成常规治疗组和黄芪治疗组两组。黄芪治疗组在常规治疗基础上加用复方黄芪注射液治疗。治疗前和治疗后不同时间点分别检测患者血清NES、MBP和S-100B浓度,并行GCS评分，3个月后行GOS评分；同时检测96例健康成人血清的NES、MBP和S-100B的浓度，然后对所得资料进行统计学分析。结果急性重型颅脑损伤患者血清的NES、MBP和S-100B的浓度均显著高于健康成年人（P〈0．05）。治疗后黄芪治疗组血清NSE、MBP和S-100B均低于常规治疗组，差异均有显著性意义（P〈0．05）。黄芪治疗组在入院时的GCS评分与常规治疗组比较无显著性差异（P〉0．05），但治疗后1周和2周其GCS评分显著高于常规治疗组（P〈0．05）。治疗3月后其GOS评分显著高于常规治疗组（P〉0．05）。结论黄芪能降低急性重型颅脑损伤患者血清NSE，MBP，S-100B含量，并能改善患者的预后。

Effect of Compound Astragalus Membranaceus Injection on Concentrations of Serum NSE, MBP and S-100B in Patients with Acute Severe Craniocerebral Injury

Objective To observe the effect of compound Abstragalus Membranaceus injection on the concentrations of serum neuron specific enolase (NSE), myelin basic protein (MBP) and S-100 protein B(S-100B) in the patients with acute severe craniocerebral injury. Methods One hundred and ninety-six patients with acute severe craniocerebral injury were randomly divided into two groups, i.e. treatment group, where 98 patients received compound Abstragalus Membranaceus injection plus conventional treatment, and control group, where 98 patients only received conventional treatment. The concentrations of the serum NSE, MBP and S-100B were determined and the GCS was evaluated respectively before the treatment and at the different time after the treatment in all the patients and 96 healthful adults. The GOS was evaluated in all the patients 3 months after the treatment. Results The concentrations of the serum NSE, MBP and S-100B in the patients with acute severe craniocerebral inury were significantly higher than those in the healthful adults (P<0.05). The concentrations of serum NSE, MBP and S-100B in the treated group were significantly lower than those in the control group after the treatment (P<0.05). The GCS of the patients in the treatment group were significantly higher than that in the control group 1 and 2 weeks after the treatment (P<0.05). The GOS of patients in the treatment group were significantly higher than that in the control group 3 months after the treatment (P<0.05). Conclusions Compound Abstragalus Membranaceus injection can reduce the concentrations of serum NSE, MBP and S-100B, and improve the prognosis in the patients with acute severe craniocerebral injury.